MAPT and Alzheimer disease: Of interest, our study provides information on the frequency of CU older adults who could qualify for the clinical stage 2 of the biological AD continuum in our samples, with 18% (13%–22%) of participants endorsing (multiple) SCD‐plus features and having abnormal Aβ levels (SCD+Aβ+), whereas only 6% (4%–8%) of participants also have abnormal tau levels (SCD+Aβ+T+).